• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Heron Therapeutics Inc.

    8/6/24 4:35:32 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    S-8 1 hrtx-20240806.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 6, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    Heron Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    94-2875566

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    4242 Campus Point Court, Suite 200, San Diego, California

    (Address of Principal Executive Offices)

     

     

     

    92121

    (Zip Code)

    2007 Equity Incentive Plan, as amended

    1997 Employee Stock Purchase Plan, as amended

    Non-Plan Inducement Stock Option Grants

    Non-Plan Inducement Restricted Stock Unit Grants

    (Full Title of the Plans)

    Ira Duarte

    Executive Vice President, Chief Financial Officer

    Heron Therapeutics, Inc.

    4242 Campus Point Court, Suite 200

    San Diego, California 92121

    (Name and address of agent for service)

    (858) 251-4400

    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed to register an additional 10,110,000 shares of common stock, par value $0.01 per share (“Common Stock”), of Heron Therapeutics, Inc. (the “Registrant”), consisting of:

    •
    7,500,000 shares of Common Stock issuable pursuant to the Registrant’s 2007 Equity Incentive Plan, as amended (the “2007 Plan”), pursuant to an amendment to the 2007 Plan approved by the stockholders of the Registrant on June 13, 2024;

     

    •
    1,200,000 shares of Common Stock issuable pursuant to the Registrant’s 1997 Employee Stock Purchase Plan, as amended (the “1997 ESPP”), pursuant to an amendment to the 1997 ESPP approved by the stockholders of the Registrant on June 13, 2024; and

     

    •
    1,410,000 shares of Common Stock issuable upon the exercise of outstanding options and vesting of restricted stock units, which were granted to certain employees outside of a plan as inducement equity awards (the “Inducement Awards”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were approved by the Compensation Committee of the Registrant’s Board of Directors (the “Board”), as an inducement material to such employees entering into employment with the Registrant.

     

    The shares of Common Stock previously reserved for issuance under the 2007 Plan were registered on the Registrant’s Registration Statements on Form S-8 (File Nos. 333-148660, 333-167515, 333-176365, 333-198853, 333-206165, 333-214503, 333-219830, 333-233023, 333-259518, 333-267352 and 333-273059) filed with the Securities and Exchange Commission (the “SEC”) on January 14, 2008, June 15, 2010, August 17, 2011, September 19, 2014, August 6, 2015, November 8, 2016, August 9, 2017, August 5, 2019, September 14, 2021, September 9, 2022, and June 30, 2023, respectively, and the shares of Common Stock previously reserved for issuance under the 1997 ESPP were registered on the Registrant’s Registration Statements on Form S-8 (File Nos. 333-35151, 333-118546, 333-127574, 333-137954, 333-148660, 333-162610, 333-176366, 333-198853, 333-206165, 333-214503, 333-219830, 333-233023, 333-259518, 333-267352 and 333-273059) filed with the SEC on September 8, 1997, August 25, 2004, August 16, 2005, October 11, 2006, January 14, 2008, October 21, 2009, August 17, 2011, September 19, 2014, August 6, 2015, November 8, 2016, August 9, 2017, August 5, 2019, September 14, 2021, September 9, 2022, and June 30, 2023, respectively (collectively, the foregoing Registration Statements are referred to herein as the “Prior Registration Statements”).

    This Registration Statement relates, in part, to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8. Pursuant to General Instruction E of Form S-8, the contents of Prior Registration Statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein, except for Items 3 and 8, which are being updated by this Registration Statement.

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8.

    2

     

     


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents have been filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”) and are incorporated herein by reference:

    •
    Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on March 12, 2024;
    •
    Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed with the SEC on May 7, 2024;
    •
    Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed with the SEC on August 6, 2024;
    •
    Current Reports on Form 8-K, filed with the Commission on January 11, 2024, January 24, 2024, March 21, 2024, and June 18, 2024;
    •
    the portions of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2024 that are specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023; and
    •
    The description of the Registrant’s Common Stock contained in Exhibit 4.5 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Commission on March 2, 2020, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. The Registrant is not incorporating by reference any reports or documents or portions thereof that are not considered to be “filed” with the Commission.

    Any statement contained herein or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    3

     

     


    Item 8. Exhibits

     

     

     

    Exhibit No.

    Description

     

     

        4.1

    Certificate of Incorporation, as amended through July 29, 2009 (incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, as Exhibit 3.1, filed on August 4, 2009)

     

     

        4.2

    Certificate of Amendment of Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 30, 2011)

     

     

        4.3

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on January 13, 2014)

     

     

        4.4

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Post-Effective Amendment to its Registration Statement on Form 8-A/A, filed on July 6, 2017)

     

     

        4.5

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018, as Exhibit 3.6, filed on February 22, 2019)

     

     

        4.6

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 12, 2023)

     

     

        4.7

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 18, 2024)

     

     

     

        4.8

     

    Amended and Restated Bylaws (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on February 8, 2019)

     

     

        5.1

    Opinion of K&L Gates LLP*

     

     

      23.1

    Consent of K&L Gates LLP (included in Exhibit 5.1 above)*

     

     

      23.2

    Consent of WithumSmith+Brown, PC, independent registered public accounting firm*

     

     

      24.1

    Power of Attorney (included on the signature page)*

     

     

      99.1

    Amended and Restated 2007 Equity Incentive Plan*

     

     

      99.2

    Amended and Restated 1997 Employee Stock Purchase Plan*

     

     

      99.3

    Form of Inducement Notice of Grant of Stock Options and Option Agreement*

     

     

      99.4

    Form of Inducement Notice of Grant of Restricted Stock Units and Restricted Stock Unit Agreement*

     

     

    107.1

    Filing Fee Table*

     

    *

    Filed herewith.

     

    4

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 6, 2024.

     

     

     

    HERON THERAPEUTICS, INC.

    (Registrant)

     

     

    By:

    /s/ Ira Duarte

     

    Ira Duarte

    Executive Vice President, Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Craig Collard and Ira Duarte, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    5

     

     


     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Craig Collard

    Craig Collard

    Chief Executive Officer and Director

    (Principal Executive Officer)

    August 6, 2024

     

     

     

    /s/ Ira Duarte

    Ira Duarte

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    August 6, 2024

     

     

     

    /s/ Adam Morgan

    Adam Morgan

    Chairman of the Board of Directors

    August 6, 2024

     

     

     

    /s/ Sharmila Dissanaike

    Sharmila Dissanaike

    Director

    August 6, 2024

     

     

     

    /s/ Craig Johnson

    Craig Johnson

    Director

    August 6, 2024

     

     

     

    /s/ Susan Rodriguez

    Susan Rodriguez

    Director

    August 6, 2024

     

     

     

    /s/ Christian Waage

    Christian Waage

    Director

    August 6, 2024

     

    6

     

     


    Get the next $HRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/9/2025$6.00Buy
    H.C. Wainwright
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings

    $HRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Rubric Capital Management Lp bought $3,580,838 worth of shares (2,387,225 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 6:00:17 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morgan Adam bought $2,649,819 worth of shares (1,766,546 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 5:02:36 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    11/21/23 12:19:26 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Heron Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $6.00

    6/9/25 7:51:39 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00

    6/13/24 7:14:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on Heron Therapeutics with a new price target

    CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00

    4/23/24 6:55:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cusack Thomas was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:07 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Duarte Ira

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:10 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Johnson Craig A was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:08 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

    CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. "We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®," said Craig Collard, Chief Executive Officer of Heron. "In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year." Preliminary Fourth Quarter and Full Year 2025 Updates Net revenue of approximately $40.5 million for the

    1/9/26 9:29:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

    APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ("NK-1") antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or added to a multimodal regimen, recognized as significantly reducing the risk of PONV, and aprepitant monotherapies are noted as more effective compared to 5-HT3 receptor antagonists for postoperative vomiting preventionPost-discharge nausea and vomiting (PDNV) recognized as a significant risk to discharged postoperative patients and the role of long-acting antiemetic strategies highlighted as extending protection beyond the recovery room and into the

    12/4/25 8:15:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

    Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage

    11/4/25 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Heron Therapeutics Inc.

    SCHEDULE 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    1/30/26 2:20:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

    1/9/26 1:08:24 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Heron Therapeutics Inc.

    SCHEDULE 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    11/26/25 10:15:35 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Financials

    Live finance-specific insights

    View All

    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

    Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage

    11/4/25 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under

    10/21/25 4:20:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

    Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 millionDelivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0 million - $12.0 million to $9.0 million - $13.0 millionZYNRELEF® unit demand grew 6.3% in Q2 2025 as compared to Q1 2025, with revenue impacted by a temporary wholesaler adjustment from the 400mg VAN transition; momentum building ahead of expanded commercial initiatives and dedicated sales team in Q3 2025APONVIE® unit demand grew 19% in Q2 2025 as compared to Q1 2025, supported by increased adoption in hospital sys

    8/8/25 7:45:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

    CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

    4/28/25 6:55:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

    SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera

    11/4/24 5:00:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Heron Therapeutics Inc.

    SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    11/12/24 9:32:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

    SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    5/31/24 11:08:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

    SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    2/14/24 4:37:34 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care